Cleared Special

K983701 - MODIFICATION TO ABUSCREEN ONLINE FOR CANNABINOIDS

K983701 is an FDA 510(k) clearance for MODIFICATION TO ABUSCREEN ONLINE FOR CA..., manufactured by Roche Diagnostic Systems, Inc.. The device is a Class 2 Toxicology device with product code LDJ cleared through the Special 510(k) pathway after a 51-day FDA review.

K983701 · Roche Diagnostic Systems, Inc. · Toxicology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Dec 1998
Decision
51d
Days
Class 2
Risk

K983701 is an FDA 510(k) clearance for the MODIFICATION TO ABUSCREEN ONLINE FOR CANNABINOIDS. Classified as Enzyme Immunoassay, Cannabinoids (product code LDJ), Class II - Special Controls.

Submitted by Roche Diagnostic Systems, Inc. (Somerville, US). The FDA issued a Cleared decision on December 11, 1998 after a review of 51 days - a notably fast clearance cycle.

This device falls under the Toxicology FDA review panel, regulated under 21 CFR 862.3870 - the FDA toxicology device framework. As a Special 510(k), this submission covers a manufacturer modification to an existing cleared device rather than a new device introduction.

Device pattern: Iterative device modification. Low regulatory complexity profile. This Special 510(k) clearance confirms that the manufacturer's modifications remained within the established regulatory envelope of the original cleared device.

View all Roche Diagnostic Systems, Inc. devices

FDA 510(k) Submission Details - K983701

510(k) Number K983701 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received October 21, 1998
Decision Date December 11, 1998
Days to Decision 51 days
Submission Type Special
Review Panel Toxicology (TX)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
36d faster than avg
Panel avg: 87d · This submission: 51d
Pathway characteristics
Modification to existing cleared device.

LDJ Device Classification - Class 2, Special Controls

Product Code LDJ Enzyme Immunoassay, Cannabinoids
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 862.3870
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Toxicology devices follow this clearance model.

Regulatory Peers - LDJ Enzyme Immunoassay, Cannabinoids

All 120
Devices cleared under the same product code (LDJ) and FDA review panel - the closest regulatory comparables to K983701.
MICRO-STRIP FOR MARIJUANA METABOLITES
K991516 · Microdiagnostics, Inc. · Aug 1999
RAPIDONE - MARIJUANA TEST
K990818 · American Bio Medica Corp. · Jul 1999
REDI-TEST THC
K990870 · Redwood Biotech, Inc. · Apr 1999
DBEST TETRAHYDROCANNABINOL TEST KIT
K983188 · Ameritek, Inc. · Nov 1998
UBI MAGIWEL MARIJUANA METABOLITES
K973154 · United Biotech, Inc. · Jul 1998
GENIE CUP INTEGRATED SCREENING DEVICE
K980836 · Applied Technology Ventures, LLC · Jun 1998